Tofacitinib in refractory adult-onset Still's disease: 14 cases from a single centre in China

Ann Rheum Dis. 2020 Jun;79(6):842-844. doi: 10.1136/annrheumdis-2019-216699. Epub 2020 Feb 20.

Authors

Qiongyi Hu^#¹, Mengyan Wang^#¹, Jinchao Jia¹, Jialin Teng¹, Huihui Chi¹, Tingting Liu¹, Hong-Lei Liu¹, Xiaobing Cheng¹, Junna Ye¹, Yutong Su¹, Yue Sun¹, Zhuochao Zhou¹, Liyan Wan¹, Zhihong Wang¹, Fan Wang¹, Hui Shi², Chengde Yang²

Affiliations

¹ Department of Rheumatology and Immunology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
² Department of Rheumatology and Immunology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China yangchengde@sina.com shihui_sjtu@sina.com.

^# Contributed equally.

No abstract available

Keywords: DMARDs (biologic); adult onset Still's disease; treatment.

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Adolescent
Adult
Aged
Female
Humans
Janus Kinase Inhibitors / therapeutic use*
Male
Middle Aged
Piperidines / therapeutic use*
Pyrimidines / therapeutic use*
Pyrroles / therapeutic use*
Retreatment
Still's Disease, Adult-Onset / drug therapy*

Substances

Janus Kinase Inhibitors
Piperidines
Pyrimidines
Pyrroles
tofacitinib